<DOC>
	<DOC>NCT00730847</DOC>
	<brief_summary>This study will collect clinical data (safety and reactogenicity) of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in the local target population as per the Bureau of Food and Drugs Directive of Philippines.</brief_summary>
	<brief_title>Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs &amp; Above</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that they and/or their LAR's can and will comply with the requirements of the protocol should be enrolled in the study. A female 10 years of age and above at the time of the first vaccination. Written informed consent obtained from the subject. For subjects below the legal age of consent, written informed consent must be obtained from the parent or legal guardian (legally acceptable representative LAR) of the subject and informed assent must be obtained from the subject. Free of obvious health problems as established by medical history and historydirected physical examination before entering into the study. Subjects of childbearing potential must not be pregnant. Subjects must be of nonchildbearing potential, or if the subject is of childbearing potential, she must be abstinent (and if so, this must be documented in the source documents at each vaccination visit) or must be using adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Concurrently participating in another clinical study at any time during the study period, in which the subject has been or will be exposed to an investigational or noninvestigational product (pharmaceutical product or device). Pregnant or breastfeeding. Planning to become pregnant or likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive prevention during the study period and up to two months after the last vaccine dose. History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccine. Hypersensitivity to latex (found in syringetip cap and plunger). Known acute or chronic, clinically significant neurologic, haematological, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests. Cancer or autoimmune disease under treatment Previous vaccination against HPV or planned administration of another HPV vaccine during the study. Acute disease at the time of enrolment.</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PMS</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>Safety</keyword>
	<keyword>Prescribing Information</keyword>
	<keyword>Philippines</keyword>
	<keyword>HPV</keyword>
	<keyword>Human papillomavirus</keyword>
</DOC>